Background: Tardive dyskinesia (TD) is characterized by abnormal and involuntary movements. Importantly, TD could cause considerable personal suffering and social and physical disabilities. Aims: This meta-analysis based on randomized controlled trials (RCTs) systematically assessed the therapeutic effect and tolerability of melatonin for TD in schizophrenia. Methods: A computerized and systematical search of both Chinese (Wanfang Data, Chinese National Knowledge Infrastructure (CNKI), SINOMED) and English (PubMed, PsycINFO, Embase, Cochrane Library databases) databases, from their inception until June 8, 2017, was conducted by two independent authors. The severity of TD symptoms were the primary outcome measure and analyzed using a random effects model by the Review Manager (RevMan) Version 5.3. Quality evaluation of included RCTs was conducted using the Cochrane risk of bias and Jadad scale. The GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system recommendation grading method was used to assess the overall quality level of meta-analytic outcomes. Results: Four RCTs (n=130) were identified and analyzed. Three RCTs used double blind and 1 RCT used masked assessors using the Cochrane risk of bias, and 3 RCTs were rated as high quality based on Jadad scale. Compared with the control group, adjunctive melatonin was superior in reducing the severity of TD as measured by the Abnormal Involuntary Movement Scale (AIMS) (4 RCTs, n=130, weighted mean difference (WMD): -1.52 (95% confidence intervals (CI): -3.24, 0.20), p=0.08; I 2 =0%) although the improvement did not reach a significant level. The overall evidence quality of the improvement of TD symptoms, according to GRADE approach, was rated as "Low". The data on the ADRs and cognitive effect were limited. Conclusions: This meta-analysis shows that melatonin has potential for improving TD symptoms in schizophrenia. Future higher quality and larger RCTs are warranted to confirm the findings.
Introduction
Tardive dyskinesia (TD) can occur in up to 20% of schizophrenia patients receiving long-term antipsychotics (APs) [1] [2] [3] [4] , and is associated with considerable personal suffering and social and physical disabilities. [3] TD is characterized by abnormal and involuntary movements (such as choreiform, athetoid and rhythmic) on orofacial, extremities, or even truncal region. [5] Numerous medications for TD have been examined, but there have been no well-proven treatments. [6] The pathophysiology of APs induced TD remains controversial. Free radicals associated with low brainderived neurotrophic factor (BDNF) is probably involved in the process. [2, 7, 8] Several antioxidants, based on the free radical hypothesis of TD, have been studied for the therapeutic effects of TD, such as melatonin [6, [9] [10] [11] , vitamin B 6 [12, 13] , vitamin E [14, 15] , Ginkgo biloba (EGb) [4] and piracetam. [16, 17] Melatonin (N-acetyl-5-methoxytryptamine), a neurohormone that is secreted by the pineal gland, is a naturally occurring potent antioxidant in the brain. [5, 18] Animal model studies [19] [20] [21] suggested that melatonin is efficacious in the improvement of abnormal movements. Some randomized controlled trials (RCTs) [6, [9] [10] [11] have examined the efficacy and safety of adjunctive melatonin for schizophrenia patients with TD, but results are inconsistent.
One review [5] which examined the efficacy of melatonin for schizophrenia patients with TD based on only two RCTs [10, 11] used qualitative analysis without adequate assessment of study quality. Hence, the objective of this RCT meta-analysis was to systematically assess the efficacy and safety of adjunctive melatonin therapy for TD in schizophrenia using both English and Chinese databases since the latter is not widely known internationally.
Methods

Search Strategy and Selection Criteria
Two authors (WZ and D-BC) independently and systematically searched English (PubMed, PsycINFO, Embase, Cochrane Library databases) and Chinese databases (Wanfang Data, Chinese National Knowledge Infrastructure (CNKI), SINOMED), with each database from their inception until June 8, 2017, using the following search terms: (Tardive Dyskinesia OR Dyskinesia*, Tardive OR Dyskinesias, Tardive OR Dystonias, Tardive) AND (Mélatonine OR Melatonin). Reference lists of all identified RCTs and relevant review articles [5] for additional studies were also hand-searched.
The following selection criteria were presented using the PICOS acronym: Participants: adult schizophrenia patients with TD (≥18 years) by any diagnostic criteria. Intervention: melatonin combined with APs. Comparison: APs combined with placebo or APs monotherapy. Outcomes: the primary outcome measure was the severity of TD symptoms at endpoint assessment measured by the Abnormal Involuntary Movement Scale (AIMS). [22, 23] Key secondary outcomes were cognitive function, adverse drug reactions (ADRs), and discontinuation rate. Study design: RCTs with metaanalyzable data.
The literature from the above databases was screened by two independent authors (WZ and D-BC) using EndNote X6 software. Figure 1 presents the literature screening process. Any disagreement during this process was resolved through a discussion.
Data extraction
Two authors (D-BC and X-HY) independently and systematically extracted data and conducted quality assessment of included RCTs. Any disagreement was resolved through a discussion and consensus. Data were extracted into standard forms. Whenever data were missing for the meta-analysis, first or correspondence authors were contacted by email or telephone for additional information if possible.
Statistical methods
According to the guidelines from the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement [24] , we used the Review Manager (RevMan) Version 5.3 (http://tech.cochrane. org/revman/) to perform this meta-analysis in cases that continuous data followed normal distribution (i.e., the mean > 2 times the standard deviation when the minimum value was 0). A sensitivity analysis was conducted by excluding skewed data. For meta-analytic pooling of continuous and dichotomous outcomes, the Inverse-Variance method and Mantel-Haenszel test were used to present weighted mean differences (WMDs) and risk ratios (RRs) with their 95% confidence intervals (CIs), respectively. Intention-to-treat (ITT) data over observed cases (OC) data were preferred when both were provided. In order to compensate for study heterogeneity, the random effect model was used in all meta-analyzable outcomes. [25] Heterogeneity was presented by I-squared statistic. When I-square was greater than 50%, sensitivity, subgroup and metaregression analyses were conducted to detect the sources of heterogeneity. Furthermore, data of primary outcome were entered into a funnel plots or analyzed using Egger's test [26] to test Publication bias. All analyses were two tailed, with significance level set at 0.05.
Assessment of study quality
The methodological quality of the RCTs was assessed using the Cochrane risk of bias assessment tool [27] with 7 dimension as follows: (a) random sequence generation; (b) allocation concealment; (c) blinding of the subjects and the treatment providers; (d) blinding of the result evaluators); (e) incomplete results data; (f) selective reporting; (g) other potential risks. Furthermore, the Jadad scale was used to assess study quality. [28] High and low quality of included RCTs were defined as Jadad score ≥3 and <3, respectively. In addition, the overall evidence quality of all meta-analyzable outcomes was
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Results of the search
The characteristics of included studies
Three double-blinded trials (Castro 2011; Shamir 2000; Shamir 2001 ) and one rater masked trial (Zhu 2010) compared adjunctive melatonin (n=67) and control groups (n=63) ( Table 1 ). The weighted mean treatment duration was 9.8 weeks (range=4-12 weeks) ( Table  1) . Of the 4 RCTs , two RCTs (Shamir 2000; Shamir 2001) were conducted in Israel (n=41), one in China (Zhu 2010, n=76 ) and one in Venezuela (Castro 2011, n=13), respectively. While 24 patients in Shamir 2001 were eligible, 22 patients were described and analyzed because 2 patients were discharged from the hospital before initiation of the study.
Patient characteristics
The weighted mean age was 61.3 years (range =57.6-74.0 years) (Table 1) • 132 • (n=3, 2.3%) and rehabilitation institution settings (n=8, 6.2%).
Treatment characteristics
The weighted mean dosage of melatonin dosage was 9.2 mg/day (range=2.0-20.0 mg/day 
Jadad scale
The weighted mean Jadad total score of the 4 RCTs was 2.4 (range=1-5). While one RCT (Zhu 2010) was classified as low quality, 75% RCTs (n=3) (Castro 2011; Shamir 2000; Shamir 2001 ) were rated as high quality.
Primary outcome
The improvement of TD symptoms: there were differences between the two groups in terms of the AIMS total score (4 RCTs) at the treatment endpoint. 
Jadad score
Castro 2011 [9] (Venezuela)
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-Double blind -Inpatients (15%) and outpatient settings (23%) and a rehabilitation institution (62%) Shamir 2000 [10] (Israel) ADRs: Only one RCT (Zhu 2010 ) assessed ADRs using the Treatment Emergent Symptom Scale (TESS), and no group difference was found (Table 4) .
Discontinuation rate: Regarding discontinuation rate, one RCT (Shamir 2001) reported that 2 patients were discharged before the randomization.
Discussion
Main findings
Previously only one review [5] with 2 RCTs (n=41) involved the therapeutic effects and safety of adjunctive melatonin for schizophrenia patients suffering from TD, finding an advantage of melatonin in improving the severity of TD symptoms. In this meta-analysis (4 RCTs, n=130) based on English and Chinese databases, the results showed that adjunctive melatonin outperformed the control group in treating the severity of TD symptoms although the improvement did not GRADE=Grades of Recommendation, Assessment, Development, and Evaluation; WMD=weighted mean difference reach significance level. The strengths of this metaanalysis are the inclusion of two additional RCTs [6, 9] and the inclusion of Chinese databases with low quality. In addition, quality assessment of included studies using the Cochrane risk of bias [27] and Jadad scale [28] were conducted. The overall quality level of primary outcome were rated as "Low" using the GRADE approach. However, the data on the ADRs and cognitive effect were only reported in one RCT (Zhu 2010) , which limits our capacity to conduct meta-analysis.
Possible mechanism of melatonin in improving TD could be due to its potent antioxidant properties, which reduces oxidative stress, enhances BDNF levels and decreases the chance of neurotoxicity. [5] Furthermore, Zisapel's study [31] suggested that melatonin inhibits dopamine release in specific areas of the mammalian central nervous system (including retina, hypothalamus, medulla-pons, and hippocampus). Thus, melatonin could modulate dopaminergic pathways associated with movement disorders including TD.
Limitations
First, the sample sizes were relatively small and some information was limited, which failed to bring about a robust result. [32] Second, the dose-response effect of adjunctive melatonin (2 to 20mg/day) on TD symptoms could not be evaluated. Third, since all included RCTs were of short duration, ranging from 4 to 12 weeks, the long-term effects of melatonin on TD need to be examined further. Finally, we made a minor correction in the methods and made it differ from the protocol of this meta-analysis, i.e., "only randomized double blinded controlled trials were included" was changed to "only randomized controlled trials were included".
Implications
TD is irreversible, severe, and disabling, and so far no therapeutic strategies have been approved by the Food and Drug Administration (FDA). One meta-analysis of adjunctive EGb (ginkgo) [4] including 3 RCTs found adjunctive EGb could significantly reduce the severity of TD symptoms in schizophrenia. Another meta-analysis found that while adjunctive vitamin E [15] was similar with placebo in improving TD symptoms, it could significantly slow down the progression of the severity of TD symptoms in schizophrenia. Moreover, the previous systematic review [5] has explored the therapeutic effects of adjunctive melatonin, piracetam, and vitamin B6 on TD in schizophrenia. If melatonin is shown to be effective in TD, it may be a readily accessible and affordable option. However, future higher quality and larger RCTs are needed to confirm these results.
Conclusion
This meta-analysis shows that melatonin has potential for improving TD symptoms in schizophrenia. However, higher quality and larger RCTs are needed to confirm these findings, especially focusing on long-term therapeutic effects.
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